Search results
Jul 14, 2023 · INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
For people with commercial insurance or who are uninsured, we have capped copays at $35 * regardless of which Lilly insulin or insulin presentation patients use. Patients who receive a new prescription for a non-Lilly insulin should check with the manufacturer about any potential discount programs they offer. *Terms and conditions apply.
May 24, 2024 · INDIANAPOLIS, May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion.
Medical Information. To search for medical information, please select a product or browse by the listed therapeutic areas below. Product Information. Select a product. Search Medical Information. If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Oct 13, 2021 · Verzenio ® is a trademark owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates. This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Verzenio (abemaciclib) as a treatment for patients with early breast cancer and reflects Lilly ...
Authorized Lilly Specialty Distributors Contact Information. Oncology Supply p: 800. AmerisourceBergen Specialty Group. -633 7555 f: 800 -248 -8205 www.oncologysupply.com. ASD Healthcare. p: 800 -746 -6273 f: 800 -547 -9413 www.asdhealthcare.com f: 602BioCare SD p: 800 -304 -3064 -850 6215 www.biocare-us.com.
INDIANAPOLIS, May 13, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve ...
